Plague: Microbiology, Epidemiology, and Clinical Manifestations of Yersinia pestis

Causative Agent and Microbiology of Yersinia pestis

• Microbiological Classification and Morphology:

  • Yersinia pestis is a plump, gram-negative coccobacillus.

  • Cellular dimensions typically measure $1\text{--}2\,\mu\text{m}$ in length by $0.5\,\mu\text{m}$ in width.

  • Microscopic arrangement: Usually observed as single cells or in pairs.

  • Motility status: Nonmotile.

  • Staining characteristics: Displays distinct bipolar staining, giving the organism a "safety pin-like" appearance when stained with Wright's, Giemsa, or Wayson stains.

• Epidemiological Status in the United States:

  • Considered rare in the United States.

  • A total of $23$ cases were reported in the United States between $2007$ and $2011$.

  • Surveillance tracking spans cases recorded in the United States from $1970$ through $2019$

Zoonotic Transmission and Biological Vector Dynamics

• Definition of Zoonotic Disease:

  • A zoonotic disease is an infectious disease that is naturally transmissible from vertebrate animals to humans.

• Transmission Vectors and Pathways:

  • Primary animal reservoir: Rodents.

  • Primary vector: Infected fleas carrying Yersinia pestis.

  • Human infection pathways:

    • Bite of an infected flea.

    • Direct contact with contaminated tissue.

    • Inhalation of infectious droplets or aerosols.

• Flea Vector Physiology and Mechanical Blockage:

  • Yersinia pestis multiplies inside the flea, causing a bacterial mass that physically blocks the flea's proventriculus.

  • As a result of proventriculus obstruction, the flea cannot feed properly and experiences increasing agitation and frequency of biting.

  • In an effort to clear the obstruction, the flea regurgitates accumulated blood along with a mass of Yersinia pestis bacilli directly into the bloodstream of the host during feeding attempts.

Clinical Forms of the Plague

• Bubonic Plague:

  • Most common clinical form of the disease.

  • Infection mechanism: Occurs via the bite of an infected flea or when materials contaminated with Y. pestis enter through a break in the skin.

  • Clinical symptoms: Acute onset of fever, chills, weakness, headache, and painful swollen lymph nodes known as buboes located in the groin, axilla, or neck.

  • Transmissibility: Does not spread directly from person to person.

• Septicemic Plague:

  • Pathophysiology: Results from Y. pestis actively multiplying directly within the bloodstream.

  • Clinical symptoms: Systemic symptoms similar to bubonic plague (fever, chills, extreme weakness, abdominal pain, shock, bleeding into skin and organs), but explicitly lacks the swollen lymph nodes (buboes).

  • Transmissibility: Does not spread directly from person to person.

• Pneumonic Plague:

  • Most severe, virulent, and deadly form of plague.

  • Development: Can develop secondary to untreated bubonic or septicemic plague, or primarily via direct inhalation of infectious droplets.

  • Clinical symptoms: Rapidly progressing pneumonia characterized by fever, lymphadenopathy, cough, chest pain, and hemoptysis.

  • Transmissibility: Highly contagious and spreads rapidly from person to person via respiratory droplets.

  • Significant concern for potential deliberate bioweapon dissemination.

Treatment Protocols and Prophylaxis

• Importance of Rapid Intervention:

  • Early administration of antibiotic therapy is critical for survival.

  • To achieve a significant reduction in mortality, effective antimicrobial therapy must be initiated within $24\,\text{hours}$ of initial symptom onset.

• Effective Therapeutic Agents:

  • Streptomycin.

  • Gentamicin.

  • Tetracyclines.

  • Chloramphenicol.

• Post-Exposure Prophylaxis and Infection Control:

  • A $7\,\text{day}$ course of prophylactic antibiotic therapy protects individuals who have had direct, close contact with confirmed plague patients.

  • Wearing a close-fitting surgical mask provides respiratory protection against airborne droplet transmission.

  • Vaccination status: There is currently no plague vaccine available in the United States.

Biosafety Standards and Laboratory Protocols

• Biosafety Level Guidelines:

  • Patient specimens suspected of containing Yersinia pestis must be handled strictly using Biosafety Level 2 (BSL-2) practices.

  • Personal Protective Equipment (PPE) requirements include wearing gloves and gowns.

  • All specimen manipulations and subcultures must be performed inside a certified Class II Biosafety Cabinet (BSC).

  • Culture plates must be securely taped shut prior to incubation to prevent accidental exposure or release.

• Laboratory Notification Protocols:

  • Due to the highly infectious nature of Y. pestis, clinical laboratory personnel suspecting an infection must immediately contact the appropriate Laboratory Response Network (LRN) reference level laboratory.

Laboratory Response Network (LRN)

• Origins and Governance:

  • Established in $1999$ by the Centers for Disease Control and Prevention (CDC).

• Primary Mandate:

  • Maintains a cohesive network of specialized laboratories equipped to respond to biological terrorism, chemical terrorism, emerging infectious diseases, and other public health emergencies.

• Network Membership:

  • Integrates state and local public health, food testing, environmental, military, veterinary, and international laboratories.

• Core Capabilities:

  • Develops, maintains, and strengthens domestic and international laboratory infrastructure.

  • Provides standardized training, rapid diagnostic testing, timely notification protocols, and secure messaging of laboratory results.

Bioterrorism and Biological Warfare History

• Bioweapon Risk Classification:

  • Designated as a Tier 1 Select Agent—the highest risk category for agents with potential misuse as biological weapons.

  • Risk drivers: High mortality if untreated, rapid disease onset, nonspecific early clinical symptoms, and capacity for aerosolization.

  • Aerosol exposure causes primary pneumonic plague, maximizing transmissibility and lethality.

• Historical Warfare Applications:

  • Catapulting plague-infected corpses over siege walls during historical military conflicts.

  • In $1940$, Japanese warplanes dropped plague-contaminated rice and fleas over targets in China.

• Modern Biological Threat Estimates:

  • World Health Organization (WHO) models estimate that an aerosol release of $50\,\text{kg}$ of Y. pestis over a major city would cause widespread disease and mass casualties.

Historical Pandemics and Socioeconomic Impact

• Cumulative Historical Mortality:

  • Over $200\,\text{million}$ total deaths recorded across human history from plague epidemics.

• The Three Major Plague Pandemics:

  • The Justinian Plague: Emerged in $541\,\text{CE}$ in central Africa, spreading through Egypt and the Mediterranean basin. Estimated death toll: $30\text{--}50\,\text{million}$ ($541\text{--}542\,\text{CE}$); contributed significantly to the decline of the Roman Empire.

  • The Black Death (Second Pandemic): Began in $1347$ in Asia, spreading to the Crimea, Western Europe, and Russia. Estimated death toll: $200\,\text{million}$ ($1347\text{--}1351$), eradicating $30\text{--}50\%$ of Europe's total population and requiring over $200\,\text{years}$ for European population levels to recover.

  • The Third Pandemic: Emerged in $1855$ / $1894$ in Yunnan, China, spreading to Hong Kong, India, and globally. Estimated death toll: $12\,\text{million}$.

• Comparative Mortality of Major Global Epidemics and Pandemics:

  • Black Death ($1347\text{--}1351$): $200\,\text{million}$ deaths.

  • Smallpox ($1520$): $56\,\text{million}$ deaths (wiped out approximately $90\%$ of Native American populations; killed approximately $400{,}000$ people annually in Europe during the 1800s; led to the creation of the first vaccine).

  • Spanish Flu ($1918\text{--}1919$): $40\text{--}50\,\text{million}$ deaths.

  • Plague of Justinian ($541\text{--}542\,\text{CE}$): $30\text{--}50\,\text{million}$ deaths.

  • HIV/AIDS ($1981\text{--}\text{Present}$): $25\text{--}35\,\text{million}$ deaths.

  • The Third Plague ($1855$): $12\,\text{million}$ deaths.

  • COVID-19 ($2019\text{--}\text{Present}$, Johns Hopkins University estimate as of March 1, 2023): $\approx 6.9\,\text{million}$ deaths.

  • Antonine Plague ($165\text{--}180$): $5\,\text{million}$ deaths.

  • 17th Century Great Plagues ($1600$): $3\,\text{million}$ deaths.

  • Asian Flu ($1957\text{--}1958$): $1.1\,\text{million}$ deaths.

  • Russian Flu ($1889\text{--}1890$): $1\,\text{million}$ deaths.

  • Cholera 6th Outbreak ($1817\text{--}1923$): $1\,\text{million}$ deaths.

  • Japanese Smallpox Epidemic ($735\text{--}737$): $1\,\text{million}$ deaths.

  • Hong Kong Flu ($1968\text{--}1970$): $1\,\text{million}$ deaths.

  • 18th Century Great Plagues ($1700$): $600{,}000$ deaths.

  • Swine Flu ($2009\text{--}2010$): $200{,}000$ deaths.

  • Yellow Fever (Late 1800s): $100{,}000\text{--}150{,}000$ deaths.

  • Ebola ($2014\text{--}2016$): $11{,}300$ deaths.

  • MERS ($2012\text{--}\text{Present}$): $850$ deaths.

  • SARS ($2002\text{--}2003$): $770$ deaths.

• Socioeconomic Impacts of the Black Death on Europe:

  • Severe labor shortages due to sudden demographic collapse.

  • Widespread social instability, massacres, and violence.

  • Sharp decrease in market demand for manufactured goods.

  • Structural shift to a more flexible, mobile, and economically independent workforce.

  • Legal and social shifts allowing women to gain property ownership rights.

• Historical Personal Protective Equipment (Plague Doctors):

  • Plague doctors wore an early iteration of personal protective equipment: a long waxed gown, a wide-brimmed black hat, and a white beaked mask filled with aromatic substances intended to block the smell of decomposition.

  • Carried a wooden rod to examine and physically distance from infected patients.

Detailed Clinical Case Studies

Case Study 1: Occupational Research Exposure

• Patient Demographics and Presentation:

  • Age/Gender: $60\,\text{year old}$ male.

  • Initial Presentation: Outpatient clinic presentation with a $3\,\text{day}$ history of fever, body aches, and cough.

  • Medical History: Insulin-dependent diabetes mellitus.

  • Occupation: Researcher working with select biologic agents.

  • Initial Clinical Recommendation: Advised to seek emergency department evaluation due to suspicion of influenza or acute respiratory infection. Patient delayed seeking emergency care for $3\,\text{days}$.

• Emergency Department Readmission Findings:

  • Clinical Status: Alert and conversant, presenting with fever, cough, severe labored breathing, and worsening shortness of breath.

  • Vital Signs:

    • Oxygen Saturation: $92\%$ on room air.

    • Temperature: $100.9^\circ\text{F}$ ($38.3^\circ\text{C}$).

    • Heart Rate: $106\,\text{beats/min}$.

    • Respiratory Rate: $42\,\text{breaths/min}$.

    • Blood Pressure: $106/75\,\text{mmHg}$.

  • Physical Examination Findings:

    • Abdominal distention, peripheral cyanosis, and trace pedal edema.

    • Absence of lymphadenopathy, rash, or jaundice.

    • Chest Radiograph: Normal lung fields.

• Laboratory Diagnostic Results:

  • Renal Function: Clinical renal failure.

  • Complete Blood Count: Severe leukocytosis (white blood cell count: $79.2 \times 10^3/\mu\text{L}$) with a prominent left shift comprising $22\%$ band forms.

  • Hemoglobin and Platelet Count: Within normal ranges.

  • Peripheral Blood Smear: Extracellular bacteria visualized.

• Clinical Intervention and Progression:

  • Therapeutic Management: Administered IV diuretics, broad-spectrum IV antibiotics (vancomycin and piperacillin/tazobactam), and supplemental oxygen.

  • Deterioration: At $12\,\text{hours}$ post-presentation, developed severe worsening respiratory distress requiring intubation.

  • Outcome: Suffered fatal cardiac arrest $1\,\text{hour}$ after intubation.

• Post-Mortem Microbiological Identification:

  • Blood Culture Results:

    • Gram-negative bacilli isolated in $4$ of $4$ bottles.

    • Gram-positive cocci isolated in $3$ of $4$ bottles.

    • Yeast isolated in $1$ of $4$ bottles (presumed contaminant).

  • Gram-Positive Organism Identification: Identified as nutritionally variant streptococci (NVS).

  • Autopsy Findings: No anatomical signs of pneumonia, bowel perforation, or endocarditis.

  • Gram-Negative Organism Identification: $16\text{S}$ ribosomal DNA sequencing performed on the slow-growing gram-negative bacilli narrowed the identity to Yersinia pestis or Yersinia pseudotuberculosis. Infection control staff notified the California Department of Public Health (CDPH) on the same day.

Case Study 2: Pediatric Vector-Borne Exposure

• Patient Demographics and History:

  • Age/Gender: $7\,\text{year old}$ previously healthy female from southwestern Colorado.

  • Initial Presentation: Presented to ED with a $2\,\text{day}$ history of fever, fatigue, and multiple vomiting episodes.

  • Sick Contacts: None reported.

  • Environmental Exposures: Played in a crawl space and swept a chicken coop with mouse droppings $3\,\text{weeks}$ prior. Came in contact with a dead squirrel $4\,\text{days}$ prior to symptom onset.

• Emergency Department Physical and Neurological Examination:

  • Neurological Status: Confusion, intermittent delirium, visual hallucinations, emesis followed by a tonic-clonic seizure.

  • Vital Signs: Temperature $107^\circ\text{F}$, marked tachycardia, tachypnea, and hypotension (septic shock).

  • Physical Findings:

    • Clear breathing sounds; no signs of meningitis.

    • Insect bite marks observed on both flanks.

    • Large, extremely tender left inguinal lymph node without overlying erythema.

    • Held left leg in an externally rotated position due to severe pain.

• Laboratory and Diagnostic Evaluation:

  • Complete Blood Count & Chemistry: Leukocytosis, thrombocytopenia, elevated AST, elevated ALT—findings indicative of disseminated intravascular coagulation (DIC).

  • Cerebrospinal Fluid (CSF) Analysis:

    • WBC: $12\,\text{cells}/\mu\text{L}$.

    • RBC: $497\,\text{cells}/\mu\text{L}$.

    • Glucose: $57\,\text{mg/dL}$.

    • Protein: $24\,\text{mg/dL}$.

• Therapeutic Management and Outcome:

  • Initial Treatment: Parenteral therapy escalated to IV vancomycin, meropenem, and acyclovir.

  • Specific Antimicrobial Addition: Gentamicin added due to clinical concern for Yersinia pestis infection.

  • Outcome: Complete clinical recovery following targeted antimicrobial therapy.

• Microbiological and Molecular Diagnostic Confirmation:

  • Blood Culture: Positive for gram-negative, bipolar-staining rods.

  • State Public Health Laboratory Assay: Real-time PCR assays via the Laboratory Response Network (LRN) presumptively identified Yersinia pestis.

  • Confirmatory Testing: Isolation on agar confirmed as Y. pestis by bacteriophage lysis.

  • Molecular Testing on Secondary Samples: PCR tests on tracheal aspirate and CSF specimens were positive for Y. pestis, despite both samples returning negative culture results.

• Epidemiological Investigation:

  • Primary Source: Exposure to fleas from the dead squirrel.

  • Infection Mechanism: The patient laid her sweatshirt on the ground next to the dead squirrel, then later picked it up and tied it around her waist. Fleas transferred from the squirrel carcass to the sweatshirt and bit her on both flanks.